The pharmaceutical giant Eli Lilly's stock has been riding the skyrocketing demand for its weight loss injection Zepbound and ...

Healthcare giant Eli Lilly is now the first global healthcare company to hit $1 trillion in value riding on the popularity of ...

Eli Lilly, the maker of hugely popular weight loss drugs, has reached $1 trillion in value, becoming the first publicly ...

Zepbound and Mounjaro posted triple-digit revenue growth, making Lilly the first health industry giant to reach a ...

Eli Lilly posts 54% revenue growth, raises guidance, and drives innovation in obesity and diabetes care. Read here for an ...

Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by ...

Novo Nordisk et Eli Lilly mettront à disposition des entreprises leurs traitements respectifs, Zepbound et Wegovy, à compter du 1er janvier, selon Bloomberg News. Ces deux ...

These branded GLP-1 medications will be made available to both MangoRx and PeachesRx customers via Eli Lilly’s LillyDirect® Self Pay Pharmacy Solutions and Novo Nordisk’s NovoCare Pharmacy. Through ...

Eli Lilly has broken free from the Big Pharma pack. Fueled by sky-high expectations for the GLP-1 market, Lilly has achieved ...

The pharmaceutical company’s success developing medicines for obesity has swelled its worth to levels associated with tech ...

Eli Lilly stock soars on obesity drug success. See here to know why LLY remains a top pick with strong growth prospects and a ...

Eli Lilly and Co : Eli Lilly & Co a élu Carolyn R. Bertozzi au sein de son conseil d'administration, selon un dépôt auprès de la SEC.